J 2022

Fractional Flow Reserve Versus Instantaneous Wave-Free Ratio in Assessment of Lesion Hemodynamic Significance and Explanation of their Discrepancies. International, Multicenter and Prospective Trial: The FiGARO Study

KOVARNIK, Tomas, Matsuo HITOSHI, Ales KRAL, Stepan JERABEK, David ZEMANEK et. al.

Základní údaje

Originální název

Fractional Flow Reserve Versus Instantaneous Wave-Free Ratio in Assessment of Lesion Hemodynamic Significance and Explanation of their Discrepancies. International, Multicenter and Prospective Trial: The FiGARO Study

Autoři

KOVARNIK, Tomas (203 Česká republika, garant), Matsuo HITOSHI, Ales KRAL (203 Česká republika), Stepan JERABEK (203 Česká republika), David ZEMANEK (203 Česká republika), Yoshiaki KAWASE, Hiroyuki OMORI, Toru TANIGAKI, Jan PUDIL (203 Česká republika), Alexandra VODZINSKA (203 Česká republika), Marian BRANNY (203 Česká republika), Roman ŠTÍPAL (203 Česká republika, domácí), Petr KALA (203 Česká republika, domácí), Jan MROZEK (203 Česká republika), Martin PORZER (203 Česká republika), Tomas GREZL (203 Česká republika), Kamil NOVOBILSKY (203 Česká republika), Oscar MENDIZ (203 Česká republika), Karel KOPRIVA (203 Česká republika), Martin MATES (203 Česká republika), Martin CHVAL (203 Česká republika), Zhi CHEN, Pavel MARTASEK (203 Česká republika) a Ales LINHART (203 Česká republika)

Vydání

Journal of the American Heart Association, Hoboken, Wiley-Blackwell, 2022, 2047-9980

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 5.400

Kód RIV

RIV/00216224:14110/22:00129589

Organizační jednotka

Lékařská fakulta

UT WoS

000789861900023

Klíčová slova anglicky

coronary flow reserve; fractional flow reserve; instantaneous wave-free ratio

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 27. 1. 2023 10:45, Mgr. Tereza Miškechová

Anotace

V originále

Background:The FiGARO (FFR versus iFR in Assessment of Hemodynamic Lesion Significance, and an Explanation of Their Discrepancies) trial is a prospective registry searching for predictors of fractional flow reserve/instantaneous wave-free ratio (FFR/iFR) discrepancy. Methods and Results:FFR/iFR were analyzed using a Verrata wire, and coronary flow reserve was analyzed using a Combomap machine (both Philips-Volcano). The risk polymorphisms for endothelial nitric oxide synthase and for heme oxygenase-1 were analyzed. In total, 1884 FFR/iFR measurements from 1564 patients were included. The FFR/iFR discrepancy occurred in 393 measurements (20.9%): FFRp (positive)/iFRn (negative) type (264 lesions, 14.0%) and FFRn/iFRp (129 lesions, 6.8%) type. Coronary flow reserve was measured in 343 lesions, correlating better with iFR (R=0.56, P<0.0001) than FFR (R=0.36, P<0.0001). The coronary flow reserve value in FFRp/iFRn lesions (2.24 +/- 0.7) was significantly higher compared with both FFRp/iFRp (1.39 +/- 0.36), and FFRn/iFRn lesions (1.8 +/- 0.64, P<0.0001). Multivariable logistic regression analysis confirmed (1) sex, age, and lesion location in the right coronary artery as predictors for FFRp/iFRn discrepancy; and (2) hemoglobin level, smoking, and renal insufficiency as predictors for FFRn/iFRp discrepancy. The FFRn/iFRp type of discrepancy was significantly more frequent in patients with both risk types of polymorphisms (endothelial nitric oxide synthase(r)+heme oxygenase-1(r)): 8 patients (24.2%) compared with FFRp/iFRn type of discrepancy: 2 patients (5.9%), P=0.03. Conclusions:Predictors for FFRp/iFRn discrepancy were sex, age, and location in the right coronary artery. Predictors for FFRn/iFRp were hemoglobin level, smoking, and renal insufficiency. The risk type of polymorphism in endothelial nitric oxide synthase and heme oxygenase-1 genes was more frequently found in patients with FFRn/iFRp type of discrepancy.

Návaznosti

TN01000013, projekt VaV
Název: Personalizovaná medicína - diagnostika a terapie
Investor: Technologická agentura ČR, Personalizovaná medicína - diagnostika a terapie